• Inhaled RNA Nanotherapy Remodels Lung Tumor Collagen for Imm

  2026-07-27

  This study introduces an inhalable lipid nanoparticle system that delivers mRNA encoding anti-DDR1 antibody fragments and siRNA targeting PD-L1 to lung tumors. By disrupting collagen fiber alignment and immune suppression, the approach enhances T cell infiltration and antitumor efficacy, representing a significant advance in RNA-based cancer immunotherapy.

• EZ Cap™ Human PTEN mRNA: Next-Gen Platforms for Precision Tu

  2026-07-27

  Explore how EZ Cap™ Human PTEN mRNA empowers precision tumor suppressor gene mRNA strategies in cancer research. This article uniquely dissects the intersection of advanced mRNA engineering and targeted delivery, offering new perspectives on translational applications and assay decisions.

• Decoding EZ Cap Cy5 Firefly Luciferase mRNA: Tracking, Trans

  2026-07-26

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) enables precise mRNA delivery, intracellular tracking, and translation efficiency. This article uniquely connects advanced design features with practical assay optimization, integrating recent findings on colloidal stability for next-generation applications.

• GSH-Responsive MOF Nanoparticles Enable Synergistic Melanoma

  2026-07-25

  This study introduces a modular nanoplatform—ICG-loaded, PD-1 inhibitory peptide–modified MOF nanoparticles—that enables glutathione-responsive release and potent photothermal-immunotherapy for melanoma. The findings highlight a strategy that addresses limitations of monotherapy by synchronizing immune checkpoint blockade with photothermal ablation, significantly enhancing tumor suppression and immune activation.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibitor Innovat

  2026-07-24

  The reference study introduces dabigatran etexilate as the first oral direct thrombin inhibitor for stroke and venous thromboembolism prevention, addressing significant limitations of traditional anticoagulants. Its clinical efficacy, predictable pharmacology, and oral administration streamline anticoagulation management in atrial fibrillation and surgical contexts.

• Z-YVAD-FMK: Caspase-1 Inhibitor for Pyroptosis & Apoptosis A

  2026-07-24

  Z-YVAD-FMK revolutionizes apoptosis and pyroptosis research with its selectivity for caspase-1, enabling precise dissection of inflammasome pathways. This article delivers actionable workflows, troubleshooting insights, and a practical translation of key findings from recent necroptosis studies—empowering researchers to optimize inflammatory cell death assays with confidence.

• Chloramphenicol for Plasmid Selection: Protocols & Innovatio

  2026-07-23

  Chloramphenicol (2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide) remains a gold standard for plasmid selection in molecular biology, especially in studies addressing antimicrobial resistance. This article bridges advanced epidemiological findings with stepwise protocols, troubleshooting, and strategic optimization using APExBIO’s high-purity chloramphenicol.

• BCL-XL Inhibitor A-1155463: Precision Tools for Apoptosis Re

  2026-07-23

  A-1155463 empowers oncology researchers with potent, selective BCL-XL inhibition, enabling robust apoptosis induction in resistant tumor models. This article guides you through optimized experimental workflows, troubleshooting, and practical insights from cutting-edge glioblastoma research, leveraging APExBIO’s trusted quality.

• TMEM16F-Mediated Lipid Scrambling Regulates Ferroptosis & Tu

  2026-07-22

  Yang et al. reveal that TMEM16F-driven phospholipid scrambling suppresses ferroptosis by remodeling plasma membrane lipids after lipid peroxidation. The study demonstrates that inhibiting TMEM16F synergizes with immunotherapy to induce robust tumor immune rejection, suggesting new strategies for cancer treatment.

• Nebivolol hydrochloride: Reliable β1-Adrenoceptor Antagonism

  2026-07-22

  This article examines real-world laboratory challenges in β1-adrenergic receptor signaling research and demonstrates how Nebivolol hydrochloride (SKU B1341) delivers reproducible, high-purity solutions for cardiovascular pharmacology, hypertension, and heart failure models. Evidence-based Q&A scenarios address selectivity, protocol optimization, data interpretation, and supplier reliability, providing actionable insights for bench scientists.

• 10-Gingerol Triggers Ferroptosis in NSCLC via TFEB-NRF2 Axis

  2026-07-21

  This study uncovers a novel mechanism by which 10-gingerol induces ferroptosis in non-small cell lung cancer (NSCLC) cells, mediated through TFEB-driven lysosomal degradation of NRF2. These findings provide mechanistic insight into ferroptosis regulation and suggest new therapeutic opportunities for NSCLC.

• Trelagliptin Succinate Modulates Insulin Resistance via PI-3

  2026-07-21

  This study reveals how trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes by activating the PI-3K/AKT/GLUT4 pathway and adjusting adipokine profiles. These mechanistic insights refine our understanding of insulin signaling in metabolic disease, with practical implications for experimental models of phosphorylation-dependent pathways.

• (R)-MG132: Precision Negative Control for Proteasome Assays

  2026-07-20

  (R)-MG132 provides unmatched specificity as a negative control in proteasome inhibition studies, allowing researchers to distinguish true on-target effects from off-target or nonspecific responses. Its use streamlines assay validation, increases data clarity, and enhances confidence in ubiquitin-proteasome system research.

• Dihydrotestosterone (DHT): Optimizing Assays with SKU B8214

  2026-07-20

  This article addresses practical laboratory challenges in androgen receptor signaling and cell-based assays, focusing on how Dihydrotestosterone (DHT, SKU B8214) offers reproducible, data-driven solutions. Scenario-based Q&As provide evidence-backed guidance on protocol design, data interpretation, and product selection. Biomedical researchers will find actionable recommendations and protocol parameters for integrating DHT into translational workflows.

• HOXC8 Represses Pyroptosis in NSCLC by Downregulating Caspas

  2026-07-19

  Recent research has revealed that HOXC8 suppresses pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by transcriptionally repressing caspase-1 through HDAC1/2 recruitment. This mechanistic insight clarifies a novel axis in tumorigenesis, offering new strategies for studying inflammatory caspase pathways in cancer.

15816 records 1/1055 page Next 12345 下5页 Last page